VivoSeq
Other

Treatment Failure

0

Pipeline Programs↗

5

Active Trials↗

1

Companies Involved↗

Treatment Failure is an early-stage landscape with 0 programs across 1 company. The most active players are GSK.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

15

clinical trials

Completed6 · 40%
Recruiting4 · 27%
Terminated2 · 13%
Unknown status2 · 13%
Not yet recruiting1 · 7%

Clinical Trials

Trial Activity

15 trials

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
Recruiting·RRenJi Hospital·Phase 2·NCT05957757·20 enrolled
Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures
Recruiting·UUniversity of Zurich·N/A·NCT06405464·600 enrolled
RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure
Recruiting·TTianjin Medical University Second Hospital·Phase 1/2·NCT06663007·72 enrolled
Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II
Recruiting·SSichuan University·Phase 1/2·NCT06195189·40 enrolled
Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure
Not yet recruiting·HHenan Cancer Hospital·N/A·NCT06786208·55 enrolled
Malabsorption as a Cause of Iron Treatment Failure in Infants
Completed·HHaEmek Medical Center, Israel·N/A·NCT00456729·100 enrolled
Pasireotide for the Treatment of Gastrointestinal Angiodysplasia in Endoscopic Treatment Failure
Completed·—·Phase 2·NCT02622906·24 enrolled
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Completed·GSK logoGSK·Phase 3·NCT01328041·183 enrolled
A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000918·300 enrolled
Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure
Completed·LLaboratorios Silanes S.A. de C.V.·Phase 3·NCT04841096·162 enrolled
A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures
Completed·National Institutes of Health Clinical Center (CC)·Phase 1/2·NCT01185028·8 enrolled
Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF
Terminated·RRetina Research Institute, LLC·N/A·NCT01946399·10 enrolled
Lefamulin for M. Genitalium Treatment Failures
Terminated·UUniversity of Washington·Phase 1/2·NCT05111002·12 enrolled
Reason Evaluation of Initial Treatment Failure in Patients With CAP
Unknown status·PPeking Union Medical College Hospital·N/A·NCT03280004·314 enrolled
Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure
Unknown status·HHenan Cancer Hospital·Phase 2·NCT06334757·46 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)